A record of what Rajeev Agrawal said publicly, with the source. Not advice.
Pending — not yet graded
“Bearish on Indian pharma companies, particularly those in generics with high export percentages to the US, due to potential tariff impacts from Trump's policies. While the broader market impact is uncertain, the effect will be stock-specific, hitting companies with significant US export exposure harder.”
Nifty PharmaBearishCalled 24 Mar 2025
This call has no verdict yet — it is graded HIT or MISS against real price data once a close decides it. Save it above to find it again from your profile.
Read the original articleSee Rajeev Agrawal’s full track record